These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20040005)

  • 1. Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system.
    Wang Q; Pierson W; Sood P; Bol C; Cannon L; Gordon P; Saucedo J; Sudhir K
    J Interv Cardiol; 2010 Feb; 23(1):26-32. PubMed ID: 20040005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease.
    Zhang F; Dong L; Qian J; Ge J
    Ann Med; 2011 Feb; 43(1):75-9. PubMed ID: 21171912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
    Stone GW; Rizvi A; Sudhir K; Newman W; Applegate RJ; Cannon LA; Maddux JT; Cutlip DE; Simonton CA; Sood P; Kereiakes DJ;
    J Am Coll Cardiol; 2011 Jun; 58(1):19-25. PubMed ID: 21514084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.
    Wiemer M; Seth A; Chandra P; Neuzner J; Richardt G; Piek JJ; Desaga M; Macaya C; Bol CJ; Miquel-Hebert K; De Roeck K; Serruys PW
    Am Heart J; 2008 Oct; 156(4):751.e1-7. PubMed ID: 18926156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of the Xience V® everolimus-eluting coronary stent system.
    Claessen BE; Caixeta A; Henriques JP; Piek JJ
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials.
    Bezenek S; Hermiller J; Lansky A; Yaqub M; Hattori K; Cao S; Sood P; Sudhir K
    J Interv Cardiol; 2011 Aug; 24(4):326-41. PubMed ID: 21443551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
    Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
    EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus for stent-based intracoronary applications.
    Grube E; Buellesfeld L
    Rev Cardiovasc Med; 2004; 5 Suppl 2():S3-8. PubMed ID: 15184828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular response to a third generation everolimus-eluting stent.
    Wilson GJ; Huibregtse BA; Stejskal EA; Crary J; Starzyk RM; Dawkins KD; Barry JJ
    EuroIntervention; 2010 Sep; 6(4):512-9. PubMed ID: 20884440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study.
    Toutouzas K; Patsa C; Tsiamis E; Tsioufis C; Spanos A; Stefanadi E; Tentolouris C; Stefanadis C
    J Interv Cardiol; 2008 Oct; 21(5):388-94. PubMed ID: 18705639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.